Pasteurella multocida is the causative agent of a wide range of disease (pasteurellosis) and a zoonotic pathogen in humans. Some pathogenic bacteria are able to exploit host plasminogen for migration across tissue barriers or evade from host innate immunity. However, there is no study on host plasminogen exploitation of P. multocida. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) has been reported to be a plasminogen receptor in many pathogenic bacteria, but its role in P. multocida exploiting plasminogen has not yet been characterized. The aim of this study was to detect the activity of P. multocida to exploit host plasminogen and evaluate the ability of GAPDH to act as a receptor in the recruitment process. P. multocida could recruit host plasminogen and exhibited plasmin activity when stimulated by urokinase. GAPDH exhibited binding activity to plasminogen. GAPDH Antiserum significantly decrease the plasminogen recruitment activity of P. multocida. In conclusion, P. multocida is able to exploit host plasminogen via GAPDH. To our knowledge, this is the first report on host plasminogen exploitation of P. multocida.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.micpath.2019.01.044 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Group a remains viable inside fibrin clots and gains access to human plasminogen for subsequent fibrinolysis and dissemination.
Microbiol Spectr
January 2025
Department of Biological Sciences, University of Notre Dame, Notre Dame, Indiana, USA.
Unlabelled: Group A (GAS) is a major human pathogen that causes several invasive diseases including necrotizing fasciitis. The host coagulation cascade initiates fibrin clots to sequester bacteria to prevent dissemination into deeper tissues. GAS, especially skin-tropic bacterial strains, utilize specific virulence factors, plasminogen binding M-protein (PAM) and streptokinase (SK), to manipulate hemostasis and activate plasminogen to cause fibrinolysis and fibrin clot escape.
View Article and Find Full Text PDFExploring Peripheral and Cardiac Immune Responses in a Pneumosepsis Mouse Model with Group A Streptococcus.
Am J Respir Cell Mol Biol
January 2025
Rostock University Medical Center, Institute of Medical Microbiology, Virology and Hygiene, Rostock, Germany.
(Group A Streptococcus, GAS) is a human pathogen that causes local and systemic infections of the skin and mucous membranes. However, GAS is also found asymptomatically in the nasopharynx of infants. GAS infections, including pharyngitis and invasive pneumosepsis, pose significant public health concerns.
View Article and Find Full Text PDFTenecteplase: biochemical and clot lysis activity comparisons.
Front Pharmacol
December 2024
Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Introduction: In the last decades, the recombinant tissue plasminogen activator alteplase has been the standard fibrinolytic treatment of acute myocardial infarction, pulmonary embolism, and acute ischemic stroke. An optimized version of alteplase, tenecteplase, has been developed by exchanging six amino acids to increase half-life, achieve higher fibrin selectivity and increase resistance to plasminogen activator inhibitor-1. Meanwhile, several products containing tenecteplase exist.
View Article and Find Full Text PDFEvaluation of binding activities of a putative lipoprotein LIC_13355 of Leptospira spp.
FEBS Open Bio
December 2024
Laboratório de Desenvolvimento de Vacinas, Instituto Butantan, São Paulo, Brazil.
Pathogenic Leptospira is the etiological cause of the zoonotic life-threatening infection called leptospirosis. The disease is spread worldwide with higher risk in tropical regions. Although leptospirosis represents a burden to the health of humans and animals, the pathogenic mechanisms of Leptospira infection are yet to be clarified.
View Article and Find Full Text PDFAnakinra efficacy in COVID-19 pneumonia guided by soluble urokinase plasminogen activator receptor: Association with the inflammatory burden of the host.
Int J Antimicrob Agents
January 2025
Fourth Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece; Hellenic Institute for the Study of Sepsis, Athens, Greece. Electronic address:
Background: Anakinra was approved by the European Medicines Agency and received Emergency Use Authorization by the United States Food and Drug Administration for patients with COVID-19 pneumonia at risk for severe respiratory failure (SRF) with blood levels of soluble urokinase plasminogen activator receptor (suPAR) ≥ 6 ng/mL. We report the final results of the phase II open-label single-arm SAVE trial in a large population.
Methods: Patients with COVID-19 pneumonia and suPAR levels ≥ 6 ng/mL received subcutaneous anakinra 100 mg once daily for 10 days.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!